Nexotech and Nucleus Biotech join forces to boost ExoGAG distribution in Germany, Switzerland and Austria

Nexotech, a company belonging to the AMSlab Group dedicated to the research, development, manufacturing, and marketing of products and services in the field of human and veterinary health, has announced a collaboration agreement with Nucleus Biotech, a German company specialized in providing reagents and services to life science researchers in academia and industry.

The agreement focuses on the distribution and sale of ExoGAG. This product allows the isolation of exosomes for biomarker research, which could help oncologists to diagnose and monitor their patients by liquid biopsy. It is a patented extracellular vesicle purification method that enables the rapid and efficient isolation of pure exosomes from liquid biopsy samples such as plasma, serum, and urine. ExoGAG uses an innovative precipitation reaction based on binding the precipitation solution and glycosaminoglycans (GAGs), which coat exosomes and other extracellular vesicles. This facilitates the isolation of complex exosomes by simple centrifugation, eliminating unwanted contaminations and allowing precise analysis of proteins or genetic material contained in the extracellular vesicles.

Marcos Engroba, Corporate Sales & Marketing Manager of AMSlab Group, expressed his enthusiasm for the agreement: “We are very pleased to close this agreement, which will allow us to extend our distribution network in countries with a long history of research. We hope to contribute with ExoGAG to simplify and enhance developments in the region”.

Dr. Michael Ehret, Managing Director of Nucleus Biotech, added: “At Nucleus Biotech we are very pleased with the new distribution partnership with NEXOTECH. Extracellular vesicles are extremely promising for the detection and screening of biomarkers in liquid biopsies. Until now, isolation methods to obtain pure EVs were tedious and expensive. With NEXOTECH’s ExoGAG precipitation solution, a technology is finally available that is easy to perform, scalable and enables accurate downstream analysis.”

This agreement marks a significant milestone in the expansion of ExoGAG’s presence in the European market, offering researchers a powerful tool to advance their studies and discoveries in cell and molecular biology.